Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer

NCT07107217 is registered in ClinicalTrials.gov with Blokhin's Russian Cancer Research Center as lead sponsor.

NCT NCT07107217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07107217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer
Lead sponsor
Blokhin's Russian Cancer Research Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2025
Completion date
December 31, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer